Biocept Inc (NASDAQ:BIOC) advanced Wednesday after announcing that it expand its pathology partnership platform.
The molecular-diagnostics company said its EmpowerTC platform now offers pathologists the ability to analyze prognostic and predictive markers on circulating tumor cells from a liquid biopsy using immunocytochemistry methods.
Shares of Biocept rose 2.9% to US$1.22 in Wednesday’s Nasdaq trading.
READ: Biocept rallies after announcing Dubai company will validate patented liquid biopsy technology
The new offering, in addition to an expanded biomarker menu, supplements the previous capabilities of Biocept's proprietary pathology partnership platform to analyze liquid biopsy biomarkers using fluorescence in situ hybridization (FISH) methods.
“We believe that our pathology partnership platform distinguishes Biocept from other liquid biopsy services, and we plan to continue to innovate and launch additional markers to expand this service further in the future,” Biocept Chief Commercial Officer Edwin Hendrick said in a statement.
Last month, Biocept announced an agreement under which a Dubai company will validate its patented liquid biopsy technology in order to perform testing for the detection of tumor biomarkers.
Contact Dennis Fitzgerald at [email protected]